Allergan Inc.: PharmaVitae Report
Allergan’s prescription sales will experience positive year-on-year growth rates until sales turn to decline following key patent expiries in 2014. Although generic erosion of Allergan’s ophthalmic franchise will drive a decline in revenues, gains generated by uptake of Botox will offset these negative trends leading to positive growth overall.
Features and benefits
- Gain insight into Allergan’s strategic outlook across the next 6 years
- Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source
Request a Sample for or Inquire before buying the report @ http://www.reportsnreports.com/reports/143558-allergan-inc-pharmavitae-report.html
Major points covered in Table of Contents of this report include
- Executive Summary
- STRATEGIC INSIGHT
- COMPANY INTRODUCTION
- SALES ANALYSIS
- FINANCIAL ANALYSIS
- PRODUCT ANALYSIS
- APPENDIX
- List of Tables
- List of Figures
Explore Comprehensive list of more than 284 Tables & Figures available in the report Allergan Inc.: PharmaVitae Report
Report Details:
Published: December 2011
No. of Pages: 85
No. of Pages: 85
Price: Single User License – US$5700 Corporate User License – US$14250
No comments:
Post a Comment